Evidence map›Paper›PMID 24865460›Full record

ArticleHuman molecular genetics2014

mTOR pathway is activated by PKA in adrenocortical cells and participates in vivo to apoptosis resistance in primary pigmented nodular adrenocortical disease (PPNAD).

Cyrille de Joussineau, Isabelle Sahut-Barnola, Frédérique Tissier, Typhanie Dumontet, Coralie Drelon, Marie Batisse-Lignier, Igor Tauveron, Jean-Christophe Pointud, Anne-Marie Lefrançois-Martinez, Constantine A Stratakis and 3 more

Open access · bronzeAbstract read
In one paragraph

Article in Human molecular genetics, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
3.4field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 43 citations in OpenAlex.

  1. The protein interaction networks of mucolipins and two-pore channels.Biochimica et biophysica acta. Molecular cell research · 2019
    Pooled it
  2. Advances in Adipose Tissue Biology.Endocrine reviews · 2026
    Review
  3. Article
  4. Treatment of Primary Pigmented Nodular Adrenocortical Disease.Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme · 2022
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Effect of beta-agonists on LAM progression and treatment.Proceedings of the National Academy of Sciences of the United States of America · 2018
    Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. GATA factors in endocrine neoplasia.Molecular and cellular endocrinology · 2016
    Review
  18. Review
  19. Review
  20. Neuron membrane trafficking and protein kinases involved in autism and ADHD.International journal of molecular sciences · 2015
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 2 countries.

Cyrille de JoussineauGénétique Reproduction et Développement (GReD), Clermont Université, Université Blaise Pascal, Clermont-Ferrand Cedex 1 63012, France, CNRS, UMR 6293, GReD, INSERM, U1103, Aubière Cedex 63171, France, GReD, INSERM, U1103, Aubière Cedex 63171, France.
Isabelle Sahut-BarnolaGénétique Reproduction et Développement (GReD), Clermont Université, Université Blaise Pascal, Clermont-Ferrand Cedex 1 63012, France, CNRS, UMR 6293, GReD, INSERM, U1103, Aubière Cedex 63171, France, GReD, INSERM, U1103, Aubière Cedex 63171, France.
Frédérique TissierInstitut Cochin, Université Paris Descartes, INSERM U1016, CNRS UMR8104, Paris 75014, France, Department of Endocrinology and Department of Pathology, Reference Center for Rare Adrenal Diseases, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris 75014, France, Department of Pathology, Hôpital Pitié-Salpêtrière, Université Pierre et Marie Curie, 75013 Paris, France.
Typhanie DumontetGénétique Reproduction et Développement (GReD), Clermont Université, Université Blaise Pascal, Clermont-Ferrand Cedex 1 63012, France, CNRS, UMR 6293, GReD, INSERM, U1103, Aubière Cedex 63171, France, GReD, INSERM, U1103, Aubière Cedex 63171, France.
Coralie DrelonGénétique Reproduction et Développement (GReD), Clermont Université, Université Blaise Pascal, Clermont-Ferrand Cedex 1 63012, France, CNRS, UMR 6293, GReD, INSERM, U1103, Aubière Cedex 63171, France, GReD, INSERM, U1103, Aubière Cedex 63171, France.
Marie Batisse-LignierGénétique Reproduction et Développement (GReD), Clermont Université, Université Blaise Pascal, Clermont-Ferrand Cedex 1 63012, France, CNRS, UMR 6293, GReD, INSERM, U1103, Aubière Cedex 63171, France, GReD, INSERM, U1103, Aubière Cedex 63171, France, Service d'Endocrinologie, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand 63003, France and.
Igor TauveronGénétique Reproduction et Développement (GReD), Clermont Université, Université Blaise Pascal, Clermont-Ferrand Cedex 1 63012, France, CNRS, UMR 6293, GReD, INSERM, U1103, Aubière Cedex 63171, France, GReD, INSERM, U1103, Aubière Cedex 63171, France, Service d'Endocrinologie, Centre Hospitalier Universitaire de Clermont-Ferrand, Clermont-Ferrand 63003, France and.
Jean-Christophe PointudGénétique Reproduction et Développement (GReD), Clermont Université, Université Blaise Pascal, Clermont-Ferrand Cedex 1 63012, France, CNRS, UMR 6293, GReD, INSERM, U1103, Aubière Cedex 63171, France, GReD, INSERM, U1103, Aubière Cedex 63171, France.
Anne-Marie Lefrançois-MartinezGénétique Reproduction et Développement (GReD), Clermont Université, Université Blaise Pascal, Clermont-Ferrand Cedex 1 63012, France, CNRS, UMR 6293, GReD, INSERM, U1103, Aubière Cedex 63171, France, GReD, INSERM, U1103, Aubière Cedex 63171, France.
Constantine A StratakisSection on Endocrinology and Genetics, PDEGEN, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA.
Jérôme BertheratInstitut Cochin, Université Paris Descartes, INSERM U1016, CNRS UMR8104, Paris 75014, France, Department of Endocrinology and Department of Pathology, Reference Center for Rare Adrenal Diseases, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris 75014, France.
Pierre ValGénétique Reproduction et Développement (GReD), Clermont Université, Université Blaise Pascal, Clermont-Ferrand Cedex 1 63012, France, CNRS, UMR 6293, GReD, INSERM, U1103, Aubière Cedex 63171, France, GReD, INSERM, U1103, Aubière Cedex 63171, France.
Antoine MartinezGénétique Reproduction et Développement (GReD), Clermont Université, Université Blaise Pascal, Clermont-Ferrand Cedex 1 63012, France, CNRS, UMR 6293, GReD, INSERM, U1103, Aubière Cedex 63171, France, GReD, INSERM, U1103, Aubière Cedex 63171, France, antoine.martinez@univ-bpclermont.fr.
Centre National de la Recherche Scientifique · FRInserm · FRGenetique Reproduction and Developpement · FREunice Kennedy Shriver National Institute of Child Health and Human Development · USSorbonne Université · FRUniversité Clermont Auvergne · FR

Funding

Molecular Genetics of Endocrine Tumors and Related DisordersZIAHD008920 · NICHD · EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT · PI STRATAKIS, CONSTANTINE A. · 2012 to 2021
$25.8M
6 · The paper itself

Abstract

Primary pigmented nodular adrenocortical disease (PPNAD) is associated with inactivating mutations of the PRKAR1A tumor suppressor gene that encodes the regulatory subunit R1α of the cAMP-dependent protein kinase (PKA). In human and mouse adrenocortical cells, these mutations lead to increased PKA activity, which results in increased resistance to apoptosis that contributes to the tumorigenic process. We used in vitro and in vivo models to investigate the possibility of a crosstalk between PKA and mammalian target of rapamycin (mTOR) pathways in adrenocortical cells and its possible involvement in apoptosis resistance. Impact of PKA signaling on activation of the mTOR pathway and apoptosis was measured in a mouse model of PPNAD (AdKO mice), in human and mouse adrenocortical cell lines in response to pharmacological inhibitors and in PPNAD tissues by immunohistochemistry. AdKO mice showed increased mTOR complex 1 (mTORC1) pathway activity. Inhibition of mTORC1 by rapamycin restored sensitivity of adrenocortical cells to apoptosis in AdKO but not in wild-type mice. In both cell lines and mouse adrenals, rapid phosphorylation of mTORC1 targets including BAD proapoptotic protein was observed in response to PKA activation. Accordingly, BAD hyperphosphorylation, which inhibits its proapoptotic activity, was increased in both AdKO mouse adrenals and human PPNAD tissues. In conclusion, mTORC1 pathway is activated by PKA signaling in human and mouse adrenocortical cells, leading to increased cell survival, which is correlated with BAD hyperphosphorylation. These alterations could be causative of tumor formation.

Indexed as

Adrenal Cortex DiseasesAdrenocorticotropic HormoneAnimalsApoptosisbcl-Associated Death ProteinCell Line, TumorCyclic AMP-Dependent Protein Kinase RIalpha SubunitDisease Models, AnimalGene Knockout TechniquesHumansMaleMechanistic Target of Rapamycin Complex 1MiceMultiprotein ComplexesPhosphorylationSignal TransductionAdrenocorticotropic Hormonebcl-Associated Death ProteinCyclic AMP-Dependent Protein Kinase RIalpha SubunitMechanistic Target of Rapamycin Complex 1Multiprotein ComplexesPRKAR1A protein, humanPrkar1a protein, mouseSirolimusTOR Serine-Threonine Kinases

Identifiers

PMID24865460
PMCPMC4184389
OpenAlexW2145446850

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.